GH Research PLC (GHRS)

USD 7.4

(-12.53%)

Market Cap (In USD)

385 Million

Revenue (In USD)

-

Net Income (In USD)

-35.58 Million

Avg. Volume

35.76 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.08-14.99
PE
-
EPS
-
Beta Value
0.741
ISIN
IE000GID8VI0
CUSIP
G3855L106
CIK
1855129
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Velichka Valcheva M.D.
Employee Count
-
Website
https://www.ghres.com
Ipo Date
2021-06-25
Details
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.